We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-063)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00034944
First Posted: May 3, 2002
Last Update Posted: May 5, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
A clinical study to determine the efficacy and safety of MK0869 in the treatment of depression.

Condition Intervention Phase
Major Depressive Disorder Drug: MK0869, aprepitant Drug: Comparator: placebo Phase 3

Study Type: Interventional
Study Design: Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Double-Blind, Multicenter, Placebo Controlled, Acute and Extension Study of 2 Doses of MK0869 in the Treatment of Patients With Major Depressive Disorder

Resource links provided by NLM:


Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • HAMD-17 total score at week 8. Tolerability.

Secondary Outcome Measures:
  • CGI-I Scale score at week 8 and at least a 50% reduction in the HAMD-17 total score.

Enrollment: 495
Actual Study Start Date: January 24, 2002
Study Completion Date: December 17, 2003
Primary Completion Date: December 17, 2003 (Final data collection date for primary outcome measure)
Detailed Description:
The duration of treatment is 8 weeks.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Major depressive disorder
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Publications:
Study Data/Documents: CSR Synopsis  This link exits the ClinicalTrials.gov site

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00034944     History of Changes
Other Study ID Numbers: 0869-063
2006_403
First Submitted: May 2, 2002
First Posted: May 3, 2002
Last Update Posted: May 5, 2017
Last Verified: May 2017

Additional relevant MeSH terms:
Disease
Depressive Disorder
Depression
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Aprepitant
Fosaprepitant
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Neurokinin-1 Receptor Antagonists
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action